Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine plus cisplatin versus docetaxel plus cisplatin in first-line treatment of advanced non-small-cell lung cancer
2004-001904-10Phase 3Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Nov 2004
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing Vinorelbine plus cisplatin with Docetaxel plus cisplatin (2 arms). Primary endpoint: Time to Treatment Failure. Started Nov 2004; status: completed.
02
Drugs
vinorelbinedocetaxelcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-001904-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001904-10.